CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-07-23 | Marshall Randall 10% owner | Sale | −1,950 | $26.58 | $52K | 641,341 |
| 2020-07-23 | Marshall Randall 10% owner | Sale | −93 | $27.29 | $3K | 641,248 |
| 2020-07-22 | Marshall Randall 10% owner | Sale | −1,297 | $26.69 | $35K | 643,366 |
| 2020-07-22 | Marshall Randall 10% owner | Sale | −75 | $27.45 | $2K | 643,291 |
| 2020-07-21 | Marshall Randall 10% owner | Sale | −223 | $26.56 | $6K | 644,663 |
| 2020-07-20 | Marshall Randall 10% owner | Sale | −2,257 | $26.70 | $60K | 645,358 |
| 2020-07-20 | Marshall Randall 10% owner | Sale | −472 | $27.68 | $13K | 644,886 |
| 2020-07-17 | Marshall Randall 10% owner | Sale | −1,601 | $26.66 | $43K | 647,615 |
| 2020-07-13 | Marshall Randall 10% owner | Sale | −2,145 | $27.13 | $58K | 649,216 |
| 2020-07-10 | Marshall Randall 10% owner | Sale | −2,659 | $27.41 | $73K | 651,361 |
| 2020-07-10 | Shefferman Jesse CEO and President | Grant or award · Stock Option (Right to Buy) | +111,250 | 111,250 | ||
| 2020-06-09 | Levy Richard S Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-06-09 | SARGEN GREGORY Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-06-09 | Solomon Michael Edward Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-06-09 | GARCEAU ROGER Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-06-09 | Braunstein Scott Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-06-09 | BESHAR LUKE M Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2020-02-11 | Davis Blaine Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +94,000 | 94,000 | ||
| 2020-01-10 | Solomon Michael Edward Director | Grant or award | +26,500 | 26,500 | ||
| 2020-01-10 | Shefferman Jesse CEO and President | Grant or award · Stock Option (Right to Buy) | +111,250 | 111,250 |
Page 15 of 17 · 335 trades